215 F. Supp. 3d 670
N.D. Ill.2016Background
- Plaintiff Stephanie Leiner sues on behalf of herself and a putative class under the Illinois Consumer Fraud and Deceptive Business Practices Act (ICFA), alleging defendant labeled two “Bedtime Bath Products” as “clinically proven” to help babies sleep when they were not clinically tested.
- Leiner alleges she purchased the products (including paying a premium) based on the labeling and advertising and attached the labels to her complaint.
- Defendant moved to dismiss the complaint and to strike class allegations, arguing lack of Article III standing for injunctive relief and challenges to the pleadings and class suitability.
- Defendant contended the “clinically proven” statements were true or at least adequately substantiated and that Rule 9(b) particularity was unmet.
- The court treated merits attacks (e.g., sufficiency of testing) as inappropriate on a motion to dismiss where plaintiff alleges no clinical testing of the products themselves, only testing of a “routine.”
- The court denied the motion to dismiss and to strike class allegations, finding plaintiff sufficiently alleged injury, pleaded with required particularity, and raised class issues premature at this stage.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Article III standing for injunctive relief | Leiner alleges a cognizable injury from deception and retains standing to seek relief and represent a class | Defendant says Leiner lacks standing because she is no longer likely to purchase the product and disavows future harm | Court: standing exists; Arreola distinguishes standing from entitlement to relief; class representative adequacy decided at certification stage |
| Temporal scope of class (pre-2014 purchases) | Class may include earlier purchasers; plaintiff's standing is not limited to her own purchase date | Defendant says plaintiff cannot represent claims arising before her own purchase (2014) | Court: defendant’s standing argument fails under Arreola; issue of representativeness reserved for class certification |
| Falsity/substantiation of “clinically proven” claim | Plaintiff alleges products themselves were not clinically tested and labeling was deceptive | Defendant argues statements were true or sufficiently substantiated (merits) | Court: merits challenge premature on motion to dismiss; plaintiff alleges lack of clinical testing (not merely flawed methodology) |
| Pleading particularity under Rule 9(b) and unjust enrichment | Leiner identified labels, where/when she saw them, and alleged payment of a premium; unjust enrichment depends on ICFA claim | Defendant asserts allegations lack particularity and unjust enrichment fails without ICFA claim | Court: allegations satisfy Rule 9(b); unjust enrichment survives because ICFA claim adequately pled |
Key Cases Cited
- Arreola v. Godinez, 546 F.3d 788 (7th Cir. 2008) (distinguishes Article III standing from entitlement to relief; standing can exist even if prospective relief later proves tenuous)
- Damasco v. Clearwire Corp., 662 F.3d 891 (7th Cir. 2011) (putative class plaintiffs are entitled to develop the factual record before class certification)
- Chapman v. First Index, Inc., 796 F.3d 783 (7th Cir. 2015) (overruled Damasco on other grounds but cited for procedural context in class-certification discovery)